CALL FOR EXHIBITORS



Twelfth Annual Hematology Conference:

An Update on Selected ASH Topics

Saturday, February 6, 2016 UT Conference Center Knoxville, Tennessee

Directly-Sponsored by UT Graduate School of Medicine and UT Department of Medicine

Topics for the 2016 Conference

At the conclusion of this program, the participant should be able to

- Summarize current and ongoing study results in patients with Hemostasis/Thrombosis, Chronic Lymphocytic Leukemia, Myelodysplastic Syndromes, Multiple Myeloma, and Malignant Lymphoma
- Optimize drug therapy for cancer patients
- Identify and prevent drug interactions in cancer patients

Primarily attended by healthcare professionals practicing in

- Hematologic Oncology
- Internal Medicine

Exhibit booths will be positioned in an area directly outside the conference general session meeting room. **Due to space constraints the number of vendors will be limited.**

Your company name will be included and announced in the list of exhibitors and/or supporters

Setup time will be confirmed closer to the conference date and is dependent upon the availability of UT Conference Center on Friday, February 5.

Please Note: Pursuant to Section 6002 of the Patient Protection and Affordable Care Act , the National Physicians Payment Transparency Program, codified at 42 CFR Parts 402 and 403, was created (the "Sunshine Act"), UTGSM has enacted the following policies with regards to exhibitors at ACCME-certified activities:

- No commercial support will be used for food or beverages for attendees (food and beverages are paid for only by registration fees)
- No exhibitors can provide any gifts of any value.



REGISTRATION FORM

Twelfth Annual Hematology Conference:

Update on Selected ASH Topics Saturday, February 6, 2016

UT Conference Center, Knoxville, Tennessee

	☐ Exhibitor Booth (includes one ☐ Additional Booth (includes or ☐ Additional Exhibitors @	ne representative) \$500	
Contact Name:	Title:		
Company:			
Address:			
City:	Province/State: Postal Co	ode/Zip:	
Phone:	Fax:		
E-Mail Address:	<u></u>		
Additional Exhibitors:			
1. Name	<u> </u>		
2. Name			
3. Name			
☐ Yes, I require electricity at my booth.			
PAYMENT METHODS: □ Check Enclosed (payable to the University of Tennessee) □ Check in Process (name of company sending check) □ Credit Card: □ Mastercard / □ Visa / □ American Express Card #: Expiration Date: Cardholder's Name: Signature Code: Signature: Date:			
CANCELLATION [Initial Here] In the unlikely event that you should decide to cancel your sponsorship of this activity, the following cancellation charges will apply:			
30+ days prior t	o activity	100% refund of payment	
30-15 days prio	r to activity	50% refund of payment	
14 days prior to	arrival	0% refund of payment	

FAX OR EMAIL TO: JENNIFER RUSSOMANNO (865) 305-6823 or <u>JRussomanno@utmck.edu</u>

THE UNIVERSITY OF TENNESSEE Continuing Education and Professional Development



UT Graduate School of Medicine

1924 Alcoa Highway, D-116 Knoxville, TN 37920-6999

Tel: (865) 305-9190 Fax: (865) 305-6823

To: Prospective Exhibitors

Date: October 5, 2015

Re: Exhibiting at the Twelfth Annual Hematology Conference

The University of Tennessee Graduate School of Medicine and the UT Department of Medicine is presenting an upcoming continuing medical education activity, **Twelfth Annual Hematology Conference**: *An Update on Selected ASH Topics*. The conference will be held **February 6**, **2016** at the **UT Conference Center** in **Knoxville**, **Tennessee**.

You are invited to exhibit at this event. Each booth is \$800 (made payable "The University of Tennessee Graduate School of Medicine"), which includes the exhibit booth and one company representative. Each additional representative will be \$50 each.

The exhibit space is staged outside the conference session room. Many companies are being asked to attend. Space is limited. **We are anticipating approximately 65 participants at this year's event.**

An increased understanding of the biology and etiology of cancer has resulted in an improved ability to design therapeutic regimens. Rationally designed therapeutics, including targeted agents, modified dosing strategies, and strategic combinations of agents and therapeutic modalities, have led to improved survival without significant increases in treatment-related toxicities.

Recent studies in the treatment of patients demonstrate survival gains, and the results of recent trials suggest that new therapeutic options may improve the outcomes of patients. New biological information may lead to new treatment modalities and, in combination with statistically developed predictive models, help select patients for therapeutic options.

The conference provides an update on recent advances in the treatment of blood cancers, including a review of the biology of specific types and an update on recent clinical trials. Topics to be covered are multiple myeloma, thrombosis/hemostasis, myelodysplastic syndrome, malignant lymphoma and chronic lymphocytic leukemia. This program will provide physicians new data and treatment strategies with the aim of improving patient outcomes and quality of life.

This update occurs as soon as possible after the ASH conference while allowing time for our featured speakers to develop unique presentations combining their areas of expertise with new information obtained from the ASH presentations at the Annual Meeting and Exposition in Orlando on December 3-7, 2015.

As the accredited provider (ACCME), The University of Tennessee appreciates your consideration of this request for exhibit space. For reporting purposes, our federal tax ID number is 62-6001636.

Sincerely,

Jennifer Russomanno, CMP

CME Coordinator